BRAIDWELL LP
13F Reported Value
ⓘ$3.0B
Holdings
88
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
BRAIDWELL LP disclosed 88 positions worth $3.0B in its Form 13F-HR for Q1 2026, led by $CAI (Caris Life Sciences, Inc.) at 4.8% of the equity portfolio, followed by $GH and $RGEN. During the quarter the fund opened 30 new positions and exited 15 and a full exit from $ALGN. The portfolio is most concentrated in Healthcare (87.2% of disclosed assets). All figures are sourced directly from BRAIDWELL LP’s Form 13F-HR filing with the SEC under CIK 1920938.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 32.0#2,290
Quality
$143.2M8,009,447 sh - 36.1#2,112
Quality
$102.6M60,954,000 sh - 54.1#1,238
Quality
$98.7M101,000,000 sh - 34.6
Quality
$91.8M100,381,000 sh - 75.4
Quality
$85.9M652,121 sh - 39.2
Quality
$82.2M763,505 sh - —
Quality
$78.9M1,986,768 sh - 12.9
Quality
$77.8M1,338,452 sh - 26.8
Quality
$75.5M899,364 sh - —
Quality
$73.9M2,347,583 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Caris Life Sciences, Inc.$CAI | 32.0#2,290 | $143.2M | 8,009,447 |
 Guardant Health, Inc.$GH | 36.1#2,112 | $102.6M | 60,954,000 |
 REPLIGEN CORP$RGEN | 54.1#1,238 | $98.7M | 101,000,000 |
 NEOGENOMICS INC$NEO | 34.6 | $91.8M | 100,381,000 |
 NEUROCRINE BIOSCIENCES INC$NBIX | 75.4 | $85.9M | 652,121 |
 GLAUKOS Corp$GKOS | 39.2 | $82.2M | 763,505 |
 Centessa Pharmaceuticals plc$CNTA | — | $78.9M | 1,986,768 |
 Xenon Pharmaceuticals Inc.$XENE | 12.9 | $77.8M | 1,338,452 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 26.8 | $75.5M | 899,364 |
 Edgewise Therapeutics, Inc.$EWTX | — | $73.9M | 2,347,583 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of BRAIDWELL LP's 88 positions.
Showing top 10 of 88 holdings.
Sector Allocation
Healthcare
$2.6B
Technology
$294.2M
Other
$88.4M
Full Holdings — BRAIDWELL LP (Q1 2026)
All 88 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $CAI | Caris Life Sciences, Inc. | $143.2M | 4.8% | +2% | 32 |
| 2 | $GH | Guardant Health, Inc. | $102.6M | 3.4% | -42% | 36.1 |
| 3 | $RGEN | REPLIGEN CORP | $98.7M | 3.3% | +0% | 54.1 |
| 4 | $NEO | NEOGENOMICS INC | $91.8M | 3.1% | +0% | 34.6 |
| 5 | $NBIX | NEUROCRINE BIOSCIENCES INC | $85.9M | 2.9% | -13% | 75.4 |
| 6 | $GKOS | GLAUKOS Corp | $82.2M | 2.7% | -17% | 39.2 |
| 7 | $CNTA | Centessa Pharmaceuticals plc | $78.9M | 2.6% | -9% | — |
| 8 | $XENE | Xenon Pharmaceuticals Inc. | $77.8M | 2.6% | -27% | 12.9 |
| 9 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $75.5M | 2.5% | -29% | 26.8 |
| 10 | $EWTX | Edgewise Therapeutics, Inc. | $73.9M | 2.5% | -55% | — |
| 11 |  $IRTC | iRhythm Holdings, Inc. | $72.0M | 2.4% | +181% | 41.1 |
| 12 |  $NUVL | Nuvalent, Inc. | $71.8M | 2.4% | -15% | — |
| 13 |  $KOD | Kodiak Sciences Inc. | $69.3M | 2.3% | -12% | — |
| 14 |  $CGON | CG Oncology, Inc. | $66.7M | 2.2% | -47% | 28 |
| 15 | — | ALPHATEC HLDGS INC | $63.4M | 2.1% | NEW | — |
| 16 |  $ARGX | ARGENX SE | $62.0M | 2.1% | +174% | — |
| 17 |  $HNGE | Hinge Health, Inc. | $56.1M | 1.9% | +12% | 44.9 |
| 18 |  $ACAD | ACADIA PHARMACEUTICALS INC | $55.0M | 1.8% | +22% | 69.8 |
| 19 |  $GLUE | Monte Rosa Therapeutics, Inc. | $52.7M | 1.8% | +238% | 18.1 |
| 20 |  $KRYS | Krystal Biotech, Inc. | $47.1M | 1.6% | -10% | 75.9 |
| 21 |  $SYRE | Spyre Therapeutics, Inc. | $47.1M | 1.6% | -43% | — |
| 22 | $GH | Guardant Health, Inc. | $46.2M | 1.5% | NEW | 36.1 |
| 23 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $45.7M | 1.5% | +15% | 63.7 |
| 24 |  $GENB | Generate Biomedicines, Inc. | $44.9M | 1.5% | NEW | — |
| 25 |  $MBX | MBX Biosciences, Inc. | $44.6M | 1.5% | +47% | — |
| 26 |  $BTSG | BrightSpring Health Services, Inc. | $43.3M | 1.4% | -15% | 64.3 |
| 27 |  $CLDX | Celldex Therapeutics, Inc. | $43.0M | 1.4% | -27% | 13.2 |
| 28 | $NEO | NEOGENOMICS INC | $41.7M | 1.4% | +21% | 34.6 |
| 29 |  $APGE | Apogee Therapeutics, Inc. | $40.3M | 1.3% | -17% | — |
| 30 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $39.4M | 1.3% | +66% | — |
| 31 |  $CDNA | CareDx, Inc. | $37.7M | 1.3% | +37% | 44.8 |
| 32 |  $ISRG | INTUITIVE SURGICAL INC | $35.6M | 1.2% | -7% | 81.4 |
| 33 |  $INSP | Inspire Medical Systems, Inc. | $34.9M | 1.2% | +25% | 46 |
| 34 |  $PEN | Penumbra Inc | $34.6M | 1.1% | -4% | 69.7 |
| 35 |  $TMDX | TransMedics Group, Inc. | $32.7M | 1.1% | +4% | 70.1 |
| 36 |  $SLNO | SOLENO THERAPEUTICS INC | $32.1M | 1.1% | -19% | 46.3 |
| 37 |  $DYN | Dyne Therapeutics, Inc. | $30.5M | 1.0% | +14% | — |
| 38 |  $MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $29.0M | 1.0% | +23% | 14.5 |
| 39 |  $ILMN | ILLUMINA, INC. | $28.3M | 0.9% | -15% | 62.5 |
| 40 |  $KYMR | Kymera Therapeutics, Inc. | $28.1M | 0.9% | -26% | 29.2 |
| 41 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $28.1M | 0.9% | -17% | 74.1 |
| 42 |  $NRIX | Nurix Therapeutics, Inc. | $27.1M | 0.9% | -20% | 13.2 |
| 43 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $27.0M | 0.9% | NEW | 30.3 |
| 44 |  $DHR | DANAHER CORP /DE/ | $26.4M | 0.9% | +18% | 63.9 |
| 45 |  $ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $26.3M | 0.9% | NEW | 26.7 |
| 46 |  $TECX | Tectonic Therapeutic, Inc. | $26.2M | 0.9% | -9% | — |
| 47 |  $NTRA | Natera, Inc. | $25.8M | 0.9% | +16% | 46.4 |
| 48 |  $CRVS | Corvus Pharmaceuticals, Inc. | $25.6M | 0.9% | NEW | — |
| 49 |  $FULC | Fulcrum Therapeutics, Inc. | $24.0M | 0.8% | +2% | — |
| 50 |  $ZURA | Zura Bio Ltd | $23.7M | 0.8% | +25% | — |
| 51 |  $ATEC | Alphatec Holdings, Inc. | $23.6M | 0.8% | NEW | 37.7 |
| 52 |  $DMRA | Damora Therapeutics, Inc. | $23.2M | 0.8% | NEW | — |
| 53 |  $BSX | BOSTON SCIENTIFIC CORP | $21.7M | 0.7% | NEW | 79.9 |
| 54 |  $VERA | Vera Therapeutics, Inc. | $21.1M | 0.7% | -33% | — |
| 55 |  $BIOA | BioAge Labs, Inc. | $21.0M | 0.7% | NEW | 28.6 |
| 56 |  $CVS | CVS HEALTH Corp | $20.9M | 0.7% | -48% | 51.3 |
| 57 |  $TARS | Tarsus Pharmaceuticals, Inc. | $18.6M | 0.6% | NEW | 40.8 |
| 58 |  $ELV | Elevance Health, Inc. | $18.2M | 0.6% | NEW | 59.4 |
| 59 |  $KIDS | ORTHOPEDIATRICS CORP | $17.5M | 0.6% | +0% | 33.4 |
| 60 |  $ENGN | enGene Therapeutics Inc. | $16.7M | 0.6% | -22% | — |
| 61 |  $NKTR | NEKTAR THERAPEUTICS | $16.0M | 0.5% | NEW | 10.2 |
| 62 |  $ACHC | Acadia Healthcare Company, Inc. | $15.1M | 0.5% | NEW | 49.3 |
| 63 |  $ORIC | Oric Pharmaceuticals, Inc. | $14.3M | 0.5% | NEW | — |
| 64 |  $AVAH | Aveanna Healthcare Holdings, Inc. | $14.2M | 0.5% | NEW | 59.2 |
| 65 |  $XFOR | X4 Pharmaceuticals, Inc | $13.5M | 0.5% | -3% | 29.3 |
| 66 | — | ZENAS BIOPHARMA INC | $13.5M | 0.5% | NEW | — |
| 67 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $13.1M | 0.4% | -13% | — |
| 68 |  $EOLS | Evolus, Inc. | $12.8M | 0.4% | +0% | 30 |
| 69 |  $TGTX | TG THERAPEUTICS, INC. | $11.9M | 0.4% | NEW | 68.4 |
| 70 |  $SRZN | Surrozen, Inc./DE | $11.5M | 0.4% | -16% | — |
| 71 |  $CNC | CENTENE CORP | $10.8M | 0.4% | NEW | 52.7 |
| 72 |  $CLYM | Climb Bio, Inc. | $10.5M | 0.3% | NEW | — |
| 73 |  $CMPX | Compass Therapeutics, Inc. | $10.4M | 0.3% | -29% | — |
| 74 |  $IONS | IONIS PHARMACEUTICALS INC | $9.8M | 0.3% | NEW | 37.1 |
| 75 | — | HELIX ACQUISITION CORP III | $9.3M | 0.3% | NEW | — |
| 76 |  $VOR | Vor Biopharma Inc. | $8.3M | 0.3% | NEW | — |
| 77 |  $RVMD | Revolution Medicines, Inc. | $8.3M | 0.3% | NEW | — |
| 78 |  $GRAL | GRAIL, Inc. | $7.4M | 0.3% | +0% | 31.9 |
| 79 |  $ACRS | Aclaris Therapeutics, Inc. | $6.4M | 0.2% | NEW | 9.2 |
| 80 |  $DNLI | Denali Therapeutics Inc. | $5.7M | 0.2% | NEW | — |
| 81 | $RGEN | REPLIGEN CORP | $5.6M | 0.2% | -42% | 54.1 |
| 82 |  $HROW | HARROW, INC. | $5.5M | 0.2% | -47% | 41.6 |
| 83 |  $RVTY | REVVITY, INC. | $4.2M | 0.1% | NEW | 52.4 |
| 84 |  $CELC | Celcuity Inc. | $3.3M | 0.1% | NEW | — |
| 85 |  $PRAX | Praxis Precision Medicines, Inc. | $3.2M | 0.1% | NEW | — |
| 86 | — | ARROWHEAD PHARMACEUTICALS IN | $2.3M | 0.1% | NEW | — |
| 87 |  $LUNG | Pulmonx Corp | $970,778 | 0.0% | +0% | 23.9 |
| 88 |  $VYNE | VYNE Therapeutics Inc. | $547,356 | 0.0% | NEW | — |
New Positions (30)
$GENB Generate Biomedicines, Inc.$44.9M$RYTM RHYTHM PHARMACEUTICALS, INC.$27.0M$ESTA ESTABLISHMENT LABS HOLDINGS INC.$26.3M$CRVS Corvus Pharmaceuticals, Inc.$25.6M$ATEC Alphatec Holdings, Inc.$23.6M$DMRA Damora Therapeutics, Inc.$23.2M$BSX BOSTON SCIENTIFIC CORP$21.7M$BIOA BioAge Labs, Inc.$21.0M$TARS Tarsus Pharmaceuticals, Inc.$18.6M$ELV Elevance Health, Inc.$18.2M$NKTR NEKTAR THERAPEUTICS$16.0M$ACHC Acadia Healthcare Company, Inc.$15.1M$ORIC Oric Pharmaceuticals, Inc.$14.3M$AVAH Aveanna Healthcare Holdings, Inc.$14.2MExited Positions (15)
$ALGN ALIGN TECHNOLOGY INC
$IRWD IRONWOOD PHARMACEUTICALS INC
$RAPT RAPT Therapeutics, Inc.
$LEGN Legend Biotech Corp
$TERN Terns Pharmaceuticals, Inc.
$BIIB BIOGEN INC.
$VTYX Ventyx Biosciences, Inc.
$ICLR ICON PLC
$RLMD RELMADA THERAPEUTICS, INC.
$XNCR Xencor Inc
$CSTL CASTLE BIOSCIENCES INC
$ADPT Adaptive Biotechnologies Corp
$BLLN BillionToOne, Inc.
$ORKA Oruka Therapeutics, Inc.
$KPTI Karyopharm Therapeutics Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for BRAIDWELL LP including:
Track BRAIDWELL LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for BRAIDWELL LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: BRAIDWELL LP
13F Pro is an AI hedge fund tracker and stock research platform. For BRAIDWELL LP (SEC CIK: 1920938), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in BRAIDWELL LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.